KR960700756A - 신규한 세포 활성 조절제(novel agent for controlling gell activity) - Google Patents

신규한 세포 활성 조절제(novel agent for controlling gell activity) Download PDF

Info

Publication number
KR960700756A
KR960700756A KR1019950703985A KR19950703985A KR960700756A KR 960700756 A KR960700756 A KR 960700756A KR 1019950703985 A KR1019950703985 A KR 1019950703985A KR 19950703985 A KR19950703985 A KR 19950703985A KR 960700756 A KR960700756 A KR 960700756A
Authority
KR
South Korea
Prior art keywords
cell
agent
translation
division
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019950703985A
Other languages
English (en)
Korean (ko)
Inventor
존 로버트 노쓰
키이쓰 알란 포스터
콘라드 파드레이 퀴인
클리포드 찰스 숀
Original Assignee
죤 알. 노쓰
더 스페이우드 라보라토리 리미티드
제이. 엠. 하커
마이크로바이올로지칼 리써치 오쏘리티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 죤 알. 노쓰, 더 스페이우드 라보라토리 리미티드, 제이. 엠. 하커, 마이크로바이올로지칼 리써치 오쏘리티 filed Critical 죤 알. 노쓰
Priority claimed from PCT/GB1994/000558 external-priority patent/WO1994021300A1/en
Publication of KR960700756A publication Critical patent/KR960700756A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
KR1019950703985A 1993-03-19 1994-03-18 신규한 세포 활성 조절제(novel agent for controlling gell activity) Ceased KR960700756A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9305735.4 1993-03-19
GB939305735A GB9305735D0 (en) 1993-03-19 1993-03-19 Novel agent for controlling cell activity
PCT/GB1994/000558 WO1994021300A1 (en) 1993-03-19 1994-03-18 Novel agent for controlling cell activity

Publications (1)

Publication Number Publication Date
KR960700756A true KR960700756A (ko) 1996-02-24

Family

ID=10732382

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950703985A Ceased KR960700756A (ko) 1993-03-19 1994-03-18 신규한 세포 활성 조절제(novel agent for controlling gell activity)

Country Status (24)

Country Link
US (1) US20080070278A1 (OSRAM)
EP (1) EP0689459B1 (OSRAM)
JP (2) JP4300265B2 (OSRAM)
KR (1) KR960700756A (OSRAM)
CN (1) CN1195551C (OSRAM)
AT (1) ATE228856T1 (OSRAM)
AU (1) AU671203C (OSRAM)
BR (1) BR9406232A (OSRAM)
CA (1) CA2158647A1 (OSRAM)
CZ (1) CZ242695A3 (OSRAM)
DE (1) DE69431832T2 (OSRAM)
DK (1) DK0689459T3 (OSRAM)
ES (1) ES2183836T3 (OSRAM)
FI (1) FI954390A7 (OSRAM)
GB (1) GB9305735D0 (OSRAM)
HU (1) HU217220B (OSRAM)
IL (1) IL109045A0 (OSRAM)
IN (1) IN178499B (OSRAM)
NO (1) NO953643L (OSRAM)
NZ (1) NZ262484A (OSRAM)
PL (1) PL178895B1 (OSRAM)
PT (1) PT689459E (OSRAM)
SG (1) SG73411A1 (OSRAM)
SK (1) SK115595A3 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
CZ294376B6 (cs) * 1998-05-13 2004-12-15 Biotecon Gesellschaft Für Biotechnologische Entwic Hybridní protein a léčivo pro inhibici degranulace žírných buněk
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
GB9926875D0 (en) * 1999-11-12 2000-01-12 Microbiological Research Agenc Use of lytic toxins and toxin conjugates
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
ES2340850T3 (es) * 2003-11-14 2010-06-10 Starhome Gmbh Control de llamada terminada para itinerancia de suscriptores de telefonia movil.
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US7659092B2 (en) * 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
EP2310028B1 (en) * 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
JP7186228B2 (ja) 2018-02-26 2022-12-08 イプセン バイオファーム リミテッド 非細胞毒性プロテアーゼの注入を案内するための超音波の使用
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
BR112023020057A2 (pt) 2021-03-30 2024-03-12 Ipsen Biopharm Ltd Tratamento de dor e distúrbios inflamatórios
BR112023018473A2 (pt) 2021-03-30 2023-11-14 Ipsen Biopharm Ltd Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
EP0329184A3 (en) * 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US5045451A (en) * 1988-10-26 1991-09-03 Board Of Regents Methods for screening antibodies for use as immunotoxins
WO1990010692A1 (en) * 1989-03-15 1990-09-20 University Of Florida Monoclonal antibody for use in detection and treatment of childhood leukemia
US5300496A (en) * 1991-09-30 1994-04-05 The University Of British Columbia Complexed vanadium for the treatment of diabetes mellitus
US5877295A (en) * 1992-09-30 1999-03-02 The Center For Blood Research Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen

Also Published As

Publication number Publication date
AU671203B2 (en) 1996-08-15
CN1124929A (zh) 1996-06-19
EP0689459A1 (en) 1996-01-03
BR9406232A (pt) 1996-01-09
CZ242695A3 (en) 1996-04-17
EP0689459B1 (en) 2002-12-04
US20080070278A1 (en) 2008-03-20
HU217220B (hu) 1999-12-28
WO1994021300A2 (en) 1994-09-29
JP4740206B2 (ja) 2011-08-03
FI954390L (fi) 1995-11-17
NZ262484A (en) 1996-08-27
PT689459E (pt) 2003-04-30
DE69431832D1 (de) 2003-01-16
FI954390A0 (fi) 1995-09-18
ATE228856T1 (de) 2002-12-15
NO953643D0 (no) 1995-09-15
SK115595A3 (en) 1997-02-05
NO953643L (no) 1995-11-16
IL109045A0 (en) 1994-06-24
GB9305735D0 (en) 1993-05-05
CN1195551C (zh) 2005-04-06
CA2158647A1 (en) 1994-09-29
FI954390A7 (fi) 1995-11-17
AU671203C (en) 2003-02-27
IN178499B (OSRAM) 1997-05-03
PL310698A1 (en) 1995-12-27
DK0689459T3 (da) 2003-03-24
HU9502673D0 (en) 1995-11-28
SG73411A1 (en) 2000-06-20
JP4300265B2 (ja) 2009-07-22
JP2007302696A (ja) 2007-11-22
DE69431832T2 (de) 2003-04-10
ES2183836T3 (es) 2003-04-01
HUT76556A (en) 1997-09-29
PL178895B1 (pl) 2000-06-30
AU6217594A (en) 1994-10-11
JPH09500867A (ja) 1997-01-28

Similar Documents

Publication Publication Date Title
JP4740206B2 (ja) 細胞活性を制御するための新規作用薬
Hajjar The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen.
Ilver et al. Helicobacter pylori toxin VacA is transferred to host cells via a novel contact‐dependent mechanism
Salonen et al. Binding of fibronectin by the acute phase reactant C-reactive protein.
JP4304241B2 (ja) 末梢感覚求心性機能を修正させ得るボツリヌス毒素誘導体
Fenno et al. Cytopathic effects of the major surface protein and the chymotrypsinlike protease of Treponema denticola
Hallström et al. Complement regulator—acquiring surface protein 1 of Borrelia burgdorferi binds to human bone morphogenic protein 2, several extracellular matrix proteins, and plasminogen
ES2198750T3 (es) Conjugados de lectinas que se unen a galactosa y neurotoxinas clostridiales como analgesicos.
Zambrano et al. Borrelia burgdorferi binds to, invades, and colonizes native type I collagen lattices
Ricci et al. Free-soluble and outer membrane vesicle-associated VacA from Helicobacter pylori: Two forms of release, a different activity
GEP20012519B (en) Method for Controlling Sialylation of Proteins Produced by Mammalian Cell Culture
Arsenault et al. Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cells
EP0793506A4 (en) CELL AND SERUM PROTEIN ANCHORS AND CONJUGATES
Sommi et al. Persistence of Helicobacter pylori VacA toxin and vacuolating potential in cultured gastric epithelial cells
BG101171A (bg) Антитела, които се свързват с чревните протеини на насекомите и тяхното приложение
Boquet et al. Low pH induces a hydrophobic domain in the tetanus toxin molecule
Critchley et al. Fate of tetanus toxin bound to the surface of primary neurons in culture: evidence for rapid internalization.
US5474766A (en) Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
Chatenay‐Rivauday et al. The A and the extended VN‐terminal regions of streptococcal protein I/IIf mediate the production of tumour necrosis factor α in the monocyte cell line THP‐1
Sakaguchi et al. Antibodies against basic fibroblast growth factor inhibit the autocrine growth of pulmonary artery endothelial cells
Ricci et al. Extracellular pH modulates Helicobacter pylori-induced vacuolation and VacA toxin internalization in human gastric epithelial cells
EP0214265A1 (en) Antigens, antibodies and their uses
Ramsby et al. Fibrin induction of thrombospondin in corneal endothelial cells in vitro.
Rossetto et al. Molecular Structure and Mechanisms of Action of Botulinum Neurotoxins
RU95117960A (ru) Агент для регуляции взаимодействия клетки с ее внешним окружением, способ его получения (варианты), способ регуляции взаимодействия клетки с ее внешним окружением, способ регуляции уровня вмб (варианты), лекарство и способ его изготовления, способ лечения патофизиологического состояния

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19950919

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990317

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20001129

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20011010

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20020131

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20011010

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20001129

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I